GlassScriptPhysician profile
Erol H Ozdil
NPI 1548245798
$3,445.94
in general payments reported to CMS, 2019-2025
29 companies · $789 in 2025
The $789 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $173 · 2021: $430 · 2022: $634 · 2023: $426 · 2024: $734 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $742.37 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $403.65 | 2020-2025 | Eliquis, Camzyos |
| Amgen INC. | $398.73 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $350.39 | 2023-2025 | Cobalt Dr Mri Surescan |
| Merck Sharp & Dohme LLC | $281.44 | 2023-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $225.95 | 2021-2025 | |
| Abbott Laboratories | $205.80 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $190.11 | 2021-2024 | Xarelto |
| Esperion Therapeutics, INC. | $63.04 | 2022-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $62.81 | 2019 | |
| Lemaitre Vascular, INC. | $61.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $50.07 | 2023-2024 | Brilinta, Farxiga |
| Impulse Dynamics (USA) INC. | $41.56 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $41.29 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.60 | 2019-2023 | Lifevest |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $38.33 | 2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $31.76 | 2019 | |
| Cvrx, INC. | $30.84 | 2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $30.04 | 2025 | |
| Irhythm Technologies, INC. | $18.53 | 2022 | |
| Acist Medical Systems, INC. | $18.21 | 2022 | |
| Bardy Diagnostics, INC. | $17.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.01 | 2022 | |
| Vital Connect, INC | $16.96 | 2025 | Vitalpatch Rtm |
| Innovation Technologies INC | $16.06 | 2025 | Irrisept |
| Kiniksa Pharmaceuticals International, Plc | $15.41 | 2024 | Arcalyst |
| Agepha Pharma Fz LLC | $14.79 | 2024 | Lodoco |
| Abiomed | $12.91 | 2019 | |
| Medtronic Vascular, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erol Ozdil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.